$18.25
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Simulations Plus, Inc. engages in the provision of software and consulting services supporting drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The company is headquartered in Research Triangle Park, North Carolina and currently employs 212 full-time employees. The firm helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The firm's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Country

US

CEO

Mr. Shawn O'Connor

IPO date

1997

Employees

212

ISIN

US8292141053

Key stats

Open

$18.28

Volume

403.24K

Market cap

$370.57M

Prev. close

$18.34

Impl / hst vl

-

Open interest

$0.00

$18.23

Day’s Range

$18.39

$11.09

52W Range

$21.01

Valuation

66
Valuation score
Undervalued
P/E
-
P/S
4.59
P/B
2.76
Current ratio
5.47
Debt / Equity
-0.19
ROE
-49.30%
Gross margin
66.46%
Income growth
570.86%
FCF growth
67.37

Aug

5

Dividends

The last payment date was Aug 5, 2024

Div. per Share

$0.06

Div. Yield

0.33%

Payout Ratio

48.18%

Div. Growth YoY

0.00%

Analysts estimates

Consensus rating
Hold

The average rating from top 7 analysts indicates that stock may significantly underperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$20.23
The top 4 analysts forecasts that 12-month price may increase by 10.85%, with a low of $16.16 and a high of $26.25
$16.16
Low
$20.23
Avg
$26.25
High
Current price

Earnings

Q1 ‘26 revenue
$24.29M
Q1 ‘26 net income
$4.54M
Revenue
Net income
Previous EPS
$0.22
Estimate EPS
$0.13
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply